Partial Penectomy for Penile Cancer: Surgery, Reconstruction and Outcomes — Cost, Top Hospitals & Success Rates | MyMedicPlus

Partial penectomy is the surgical removal of the distal portion of the penis to eradicate penile cancer while preserving as much functional shaft length as possible. It is the most commonly performed surgical procedure for penile squamous cell carcinoma (SCC) confined to the glans, prepuce, or distal shaft (T1 and T2 disease), and represents the oncological gold standard when organ-sparing techniques are not feasible or have failed.

Penile cancer is rare in high-income countries — accounting for approximately 0.5% of male cancers in Europe and North America — but has an incidence of up to 4 per 100,000 men per year in parts of sub-Saharan Africa, South America, and South and South-East Asia, where it represents a significant urological malignancy. The overwhelming majority of cases are squamous cell carcinomas arising from the glans or prepuce, most commonly in association with HPV infection (particularly HPV-16 and HPV-18) and in uncircumcised men with chronic inflammatory conditions such as lichen sclerosus.

The fundamental oncological principle of partial penectomy is the achievement of a minimum 5 mm histologically clear surgical margin at the resection line, as defined by EAU (European Association of Urology) guidelines. Studies by Minhas and colleagues established that a 5 mm margin provides equivalent oncological control to the historically advocated 2 cm margin, enabling far more conservative resection and better functional outcomes. Intraoperative frozen section analysis of the resection margin is recommended at experienced centres to confirm margin clearance before wound closure.

When lymph node involvement is suspected or confirmed, partial penectomy is combined with inguinal and, in selected cases, pelvic lymph node dissection as part of a comprehensive staging and curative strategy.

Partial penectomy is performed primarily for penile malignancies that cannot be adequately managed by organ-sparing techniques, including the following specific conditions and scenarios:

• Penile squamous cell carcinoma, T1a-T2 (distal): The core indication. T1a tumours (invasion of subepithelial connective tissue, no lymphovascular invasion, non-high grade) are often amenable to organ-sparing approaches; T1b and T2 tumours (invasion of corpus spongiosum or corpora cavernosa) are typically managed by partial penectomy when located distally and when organ-sparing surgery cannot achieve adequate margins.
• Recurrence after organ-sparing treatment: Local recurrence of penile SCC after glans resurfacing, laser ablation, external beam radiotherapy, or brachytherapy is often managed by partial penectomy, which remains oncologically sound in this setting.
• High-grade (G3) or sarcomatoid penile carcinoma: High-grade histology carries increased risk of lymphovascular invasion and local recurrence; partial or total penectomy is preferred over organ-sparing techniques regardless of tumour size.
• Verrucous carcinoma (Buschke-Lowenstein tumour): A giant, locally destructive but rarely metastasising HPV-related variant; surgical excision including partial penectomy is the treatment of choice given resistance to radiotherapy.
• Carcinoma in situ (Tis) failing topical therapy: Bowen disease or erythroplasia of Queyrat refractory to topical 5-fluorouracil, imiquimod, or laser therapy may require localised surgical excision that can include glansectomy with reconstruction.
• Melanoma and other rare penile malignancies: Penile melanoma, Merkel cell carcinoma, and penile sarcoma may require surgical resection with adequate margins, the extent determined by tumour location and depth of invasion.

Eligibility for partial penectomy versus total penectomy versus organ-sparing approaches is determined by clinical staging, tumour location, histological grade, and the patient's functional and psychological priorities:

• Tumour stage T1-T2, distal location: Ideal candidates have tumours confined to the glans or distal shaft (T1b or T2) where partial amputation leaves a functional residual penile stump of at least 3 cm, which is considered the minimum for adequate sexual function and upright voiding.
• Absence of shaft involvement: Tumours involving the mid-shaft or base of the penis, or those with extensive corpora cavernosa invasion (T3), often require total rather than partial penectomy to achieve adequate oncological margins.
• No evidence of urethra or bladder involvement (T4): T4 tumours invading adjacent structures (scrotum, prostate, pubic bone) are managed by extended surgical resection and may require multidisciplinary surgical input beyond the urologist alone.
• Fitness for general or spinal anaesthesia: Partial penectomy is a surgical procedure requiring anaesthesia; standard pre-operative cardiac, pulmonary, and metabolic assessment applies. ASA grade I-III patients are typically suitable.
• Willingness to accept functional and cosmetic outcomes: Patients must receive detailed counselling about the expected post-operative functional outcomes, including residual penile length, the likelihood of achieving sexual intercourse, voiding position, and body image. Psychological support and sex therapy referral should be offered pre-operatively.
• Inguinal lymph node status: Clinical or imaging evidence of inguinal lymphadenopathy, or high pathological risk (T1b, G2-3, lymphovascular invasion) in the primary tumour, identifies patients who require bilateral inguinal lymph node dissection (ILND) concurrent with or shortly after partial penectomy.

Organ-sparing alternatives should always be considered first by a specialised multidisciplinary urology-oncology team before proceeding to penile amputation.

The surgical management of penile cancer encompasses a spectrum of procedures, from conservative organ-sparing resections to more radical penile amputations, complemented by lymph node surgery:

• Glansectomy with glans reconstruction: Removal of the glans only, with preservation of the corpora cavernosa and reconstruction of the neoglans using a split-thickness skin graft (STSG) or local flap. Appropriate for tumours strictly limited to the glans with no corporal invasion (T1 or selected T2 confined to corpus spongiosum). Associated with excellent functional and cosmetic outcomes and local recurrence rates comparable to radical surgery at experienced centres.
• Partial penectomy (distal shaft amputation): Removal of the distal shaft to achieve a 5 mm clear margin, with primary urethral spatulation and skin closure to create a functional neomeatus. The corpora cavernosa are divided and oversewn. Residual penile stump length is the key functional determinant.
• Total penectomy with perineal urethrostomy: Required for proximal, high-stage, or recurrent tumours not amenable to partial amputation. The entire penile shaft is removed and a permanent perineal urethrostomy is fashioned, requiring the patient to void in a sitting position.
• Inguinal lymph node dissection (ILND): Bilateral ILND is the standard for nodal staging in T1b-T2 disease and in all patients with palpable inguinal lymphadenopathy. Dynamic sentinel lymph node biopsy (DSNB) — a less morbid technique for non-palpable nodes — is performed at specialist centres. Modified ILND reduces wound complication rates compared to standard radical ILND.
• Pelvic lymph node dissection: Extended to the pelvis when two or more inguinal lymph nodes are positive or when extracapsular extension is confirmed on pathological analysis of inguinal specimens.
• Neoadjuvant chemotherapy before surgery: For patients with fixed, bulky (N3) inguinal or pelvic nodal disease, neoadjuvant cisplatin-based chemotherapy (TIP regimen: paclitaxel, ifosfamide, cisplatin) may downstage disease to allow subsequent salvage surgery.

Partial penectomy, when appropriate for the tumour stage, balances oncological cure with preservation of function — offering several important advantages over either total amputation or inadequate local treatment:

• High oncological control rates: With a 5 mm clear surgical margin confirmed on pathological analysis, local recurrence rates are 5–10%, equivalent to those reported with the historically advocated 2 cm margin. Five-year disease-specific survival for T1–T2N0 penile cancer after partial penectomy is 75–90%.
• Preservation of functional shaft length: Partial penectomy preserves the proximal shaft, permitting many patients to achieve sexual intercourse (particularly with a residual length of ≥4 cm) and to void in a standing position, maintaining a significant quality-of-life advantage over total penectomy.
• Definitive single-procedure cure: Unlike brachytherapy or external beam RT, which require prolonged attendance and carry risks of urethral stricture and late RT toxicity, partial penectomy is typically a single surgical procedure with definitive histological margin confirmation.
• Accurate lymph node staging: Concurrent ILND provides definitive pathological nodal staging, guiding adjuvant chemotherapy decisions and providing important prognostic information.
• Option for reconstruction: Glans reconstruction after glansectomy using a split-thickness skin graft can restore cosmetic appearance and preserve penile sensation in selected patients at specialist centres with high-volume penile cancer surgical experience.
• Relatively short recovery: Most patients are discharged within 3–7 days after uncomplicated partial penectomy, with urethral catheterisation for 10–14 days post-operatively.

Partial penectomy is a definitive but irreversible surgical procedure with functional and psychological consequences that must be thoroughly discussed pre-operatively:

• Positive surgical margins: Failure to achieve a 5 mm histologically clear margin is the most critical complication, necessitating re-excision or conversion to total penectomy. Intraoperative frozen section margin analysis at specialist centres reduces this risk substantially.
• Meatal stenosis: Narrowing of the neourethral meatus occurs in 10–20% of patients and may cause obstructed voiding, urinary tract infections, and the need for meatotomy or meatoplasty. Careful urethral spatulation and skin coverage at primary closure reduces this risk.
• Wound dehiscence and infection: Post-operative wound complications at the penile stump occur in 5–15% of patients, particularly in those with diabetes, obesity, or compromised peripheral circulation. Most resolve with wound care and antibiotics.
• Erectile dysfunction: Partial penectomy does not inherently abolish erectile function in the residual shaft, but the proximal corpora cavernosa may exhibit reduced rigidity after distal amputation. Penile rehabilitation and, if needed, prosthetic implantation into the residual stump are options.
• Local recurrence: With adequate margins, local recurrence rates are 5–10% and are higher for G3, lymphovascular-invasion-positive tumours. Salvage re-resection or total penectomy is required for local recurrence.
• Lymphoedema (post-ILND): Bilateral inguinal lymph node dissection carries a 30–50% risk of lower limb and scrotal lymphoedema, which can be chronic and functionally limiting. Lymphoedema management with compression garments and physiotherapy is important.
• Psychological impact: Body image disturbance, depression, and sexual dysfunction are reported by a substantial proportion of men after partial penectomy. Pre- and post-operative psychological support, sex therapy referral, and partner inclusion in counselling significantly improve quality-of-life outcomes.

Structured post-operative surveillance after partial penectomy serves both oncological and functional recovery goals:

• Urethral catheter management: A urethral catheter is typically left in place for 10–14 days post-operatively to allow meatal healing and prevent meatal stenosis. Voiding trials are conducted at catheter removal; urinary flow rate measurement guides further urological management.
• Wound and stump care: Daily wound inspection, dressing changes, and early mobilisation. Suture removal at 10–14 days. Wound complications are managed with topical antiseptics, antibiotics, and in severe cases, secondary surgical closure.
• Oncological surveillance: EAU guidelines recommend clinical examination of the penile stump, groin, and abdomen every 3 months for the first 2 years, every 6 months in years 3–5, and annually thereafter. Cross-sectional imaging (CT chest/abdomen/pelvis) is performed annually or when symptoms suggest recurrence.
• Inguinal monitoring: Self-examination of the inguinal regions should be taught to the patient. Any new inguinal lymphadenopathy requires prompt investigation with ultrasound-guided fine-needle aspiration cytology.
• Psychological and sexual rehabilitation: Specialist nurse follow-up, sex therapy referral, and access to a penile cancer clinical nurse specialist support post-operative adjustment. Erection-preserving strategies (vacuum erection device, PDE-5 inhibitors) and, if appropriate, penile prosthesis implantation into the residual stump are discussed at 3–6 months post-operatively.
• Lymphoedema management: Patients who have undergone ILND should be referred to a lymphoedema specialist. Early intervention with compression hosiery, manual lymphatic drainage, and skin care reduces the burden of chronic limb oedema.

The cost of partial penectomy and associated lymph node surgery varies significantly by country, institutional tier, pathological complexity, and post-operative course. Key cost determinants include:

• Country and healthcare system: Partial penectomy as a day-case or short-stay procedure typically costs USD 4,000–10,000 at accredited urological centres in India, Thailand, or Eastern Europe, compared to USD 15,000–40,000 at a specialist cancer centre in the United States or Western Europe, exclusive of anaesthesia, histopathology, and hospitalisation.
• Lymph node dissection scope: Adding bilateral inguinal lymph node dissection to partial penectomy approximately doubles the operative time and surgical complexity, increasing costs by USD 3,000–10,000 depending on the extent of dissection (sentinel node biopsy vs standard vs radical ILND).
• Intraoperative frozen section pathology: Intraoperative histological margin confirmation adds USD 500–1,500 per case but is essential oncological practice at experienced centres and reduces the need for re-excision.
• Hospitalisation duration: Uncomplicated partial penectomy requires 3–5 days of inpatient care. Complications — wound dehiscence, lymphatic leak, urinary tract infection — extend stay substantially and may add USD 2,000–8,000 per additional day at private hospitals in high-income countries.
• Glans reconstruction: Where glans reconstruction with a skin graft is performed, additional theatre time, graft harvesting, and specialist surgical input add USD 2,000–5,000 to the procedure cost.
• Oncological surveillance imaging: Annual CT imaging over 5 years and clinic consultations represent ongoing costs of USD 500–3,000 per year depending on healthcare system.

MyMedicPlus provides comparative cost data and hospital accreditation information across 48 countries to help patients identify specialist urological oncology centres.

Organ-sparing approaches are strongly preferred for eligible patients with penile cancer prior to considering penile amputation. Alternatives include:

• Glans resurfacing: For superficial tumours confined to the glans mucosa (Tis, Ta, selected T1a), the glans epithelium is excised and the raw corporeal surface is covered with a split-thickness skin graft. Recurrence rates are 10–20%, but salvage by further surgery is feasible and this approach preserves normal shaft anatomy entirely.
• Laser ablation (CO2 or Nd:YAG laser): Effective for carcinoma in situ (Tis) and T1a tumours without lymphovascular invasion. Achieves satisfactory local control in carefully selected, low-risk cases with excellent cosmetic outcomes and minimal morbidity. Requires experienced laser urology facilities and close surveillance.
• External beam radiotherapy (EBRT): An established organ-preserving alternative to surgery for penile SCC, particularly in T1-T2 tumours. Typically delivers 60–66 Gy in 30–33 fractions. Local recurrence rates are higher (20–35%) than surgery, and late complications include urethral stricture and radiation-induced fibrosis. Offers tumour control with penile preservation in patients unwilling to accept surgical amputation.
• Brachytherapy (interstitial RT): Implantation of iridium-192 wires directly into the penile tumour delivers highly localised radiation. Recommended for T1-T2 tumours ≤4 cm at experienced brachytherapy centres. Local control rates of 70–85% at 5 years have been reported, with penile preservation achieved in the majority of responders.
• Topical chemotherapy or immunotherapy: Topical 5-fluorouracil, imiquimod, or bleomycin injections are used for carcinoma in situ, achieving complete response in 50–70% of cases. Not suitable for invasive (T1 and above) penile cancer.
• Circumcision alone: Curative for tumours strictly limited to the prepuce (foreskin) with adequate free margins. A simple and highly effective treatment for preputial SCC when tumour location permits.

All penile cancer management decisions should be made at a specialist multidisciplinary penile cancer team meeting with access to urological oncology, radiation oncology, specialist nursing, and psychological services.